Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q1
$19.1M Sell
116,558
-13,233
-10% -$2.2M 0.14% 62
2016
Q4
$19M Buy
129,791
+1,709
+1% +$257K 0.15% 62
2016
Q3
$21.4M Buy
128,082
+2,847
+2% +$481K 0.18% 54
2016
Q2
$19.1M Buy
125,235
+5,135
+4% +$798K 0.18% 56
2016
Q1
$18M Buy
120,100
+14,268
+13% +$2.12M 0.18% 58
2015
Q4
$17.2M Buy
105,832
+12,103
+13% +$1.9M 0.18% 62
2015
Q3
$13M Buy
93,729
+9,661
+11% +$1.52M 0.14% 72
2015
Q2
$12.9M Buy
84,068
+9,565
+13% +$1.53M 0.14% 73
2015
Q1
$11.9M Buy
74,503
+33,196
+80% +$5.23M 0.14% 77
2014
Q4
$6.58M Buy
41,307
+2,236
+6% +$348K 0.08% 111
2014
Q3
$5.49M Buy
39,071
+3,613
+10% +$472K 0.08% 116
2014
Q2
$4.2M Buy
35,458
+863
+2% +$99.9K 0.06% 129
2014
Q1
$4.27M Buy
34,595
+797
+2% +$96.7K 0.07% 122
2013
Q4
$3.85M Buy
33,798
+3,375
+11% +$384K 0.06% 129
2013
Q3
$3.4M Buy
30,423
+7,346
+32% +$797K 0.06% 125
2013
Q2
$2.28M Buy
+23,077
New +$2.39M 0.05% 139

Other funds holding AMGN

TIAA CREF Trust's AMGN Position: Q1 2017 in Review

TIAA CREF Trust reduced its Amgen (AMGN) stake by 10% in Q1 2017, selling an estimated $2.2M and leaving 116,558 shares worth $19.1M. The position accounts for 0.14% of the portfolio, ranked #62.

TIAA CREF Trust first reported a position in AMGN in Q2 2013 and has held it in 16 quarters since. The position peaked at $21.4M in Q3 2016. 1,600 funds tracked by Wall St. Rank hold AMGN as of Q1 2017.

  • TIAA CREF Trust held 116,558 shares of Amgen worth $19.1M as of Q1 2017.
  • TIAA CREF Trust sold 13,233 Amgen shares in Q1 2017, an estimated $2.2M.
  • Amgen made up 0.14% of TIAA CREF Trust's portfolio in Q1 2017, its #62 holding.
  • TIAA CREF Trust first reported a position in Amgen in Q2 2013 and has held it in 16 quarters since.
  • TIAA CREF Trust's Amgen position peaked at $21.4M in Q3 2016.
  • 1,600 funds tracked by Wall St. Rank held Amgen as of Q1 2017.

Based on TIAA CREF Trust's 13F filing for Q1 2017, filed 3 May 2017.